Drug Profile
SSS 07
Alternative Names: anti-tumour necrosis factor monoclonal antibody - 3SBio/Pyxis Oncology; APX-001 - 3SBio/Pyxis Oncology; humanised TNF alpha monoclonal antibody - 3SBio/Pyxis Oncology; SSS-07; TNFα monoclonal antibody - 3SBio/Pyxis OncologyLatest Information Update: 24 Aug 2023
Price :
$50
*
At a glance
- Originator Epitomics
- Developer 3SBio; Pyxis Oncology
- Class Antirheumatics; Monoclonal antibodies
- Mechanism of Action Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Rheumatoid arthritis
Most Recent Events
- 23 Aug 2023 Apexigen has been acquired and merged into Pyxis Oncology
- 06 Dec 2021 Phase-II clinical trials in Rheumatoid arthritis in China (SC) (3SBio pipeline, December 2021)
- 02 Feb 2021 SSS 07 is still in phase I development for Rheumatoid arthritis in China (3SBio pipeline, February 2021)